Search Results - "MILLER, T. P"

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213 by Bernstein, S.H., Epner, E., Unger, J.M., LeBlanc, M., Cebula, E., Burack, R., Rimsza, L., Miller, T.P., Fisher, R.I.

“…Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell…”
Get full text

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices by Nooka, A.K., Nabhan, C., Zhou, X., Taylor, M.D., Byrtek, M., Miller, T.P., Friedberg, J.W., Zelenetz, A.D., Link, B.K., Cerhan, J.R., Dillon, H., Sinha, R., Shenoy, P.J., Levy, D., Dawson, K., Hirata, J.H., Flowers, C.R.

“…Because follicular lymphoma (FL) patients have heterogeneous outcomes, the FL international prognostic index (FLIPI) was developed to risk-stratify patients…”
Get full text

Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma by Miller, Thomas P, Dahlberg, Steve, Cassady, J. Robert, Adelstein, David J, Spier, Catherine M, Grogan, Thomas M, LeBlanc, Michael, Carlin, Susan, Chase, Ellen, Fisher, Richard I

“…Patients with intermediate- or high-grade non-Hodgkin's lymphoma can be cured with doxorubicin-containing combination chemotherapy. 1 The cure rate varies…”
Get full text

Evaluating Use of Ground‐Penetrating Radar for Identifying Subsurface Flow Pathways by Gish, T. J., Dulaney, W. P., Kung, K.-J. S., Daughtry, C. S. T., Doolittle, J. A., Miller, P. T.

“…Complex interactions between soil heterogeneity and soil water movement have inhibited the development of a methodology to accurately monitor subsurface water…”
Get full text

Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease by PRESS, Oliver W, LEBLANC, Michael, LICHTER, Allen S, GROGAN, Thomas M, UNGER, Joseph M, WASSERMAN, Todd H, GAYNOR, Ellen R, PETERSON, Bruce A, MILLER, Thomas P, FISHER, Richard I

“…The management of early-stage Hodgkin's disease in the United States is controversial. To evaluate whether staging laparotomy could be safely avoided in…”
Get full text

A Clinical Analysis of Two Indolent Lymphoma Entities: Mantle Cell Lymphoma and Marginal Zone Lymphoma (Including the Mucosa-Associated Lymphoid Tissue and Monocytoid B-Cell Subcategories): A Southwest Oncology Group Study by Fisher, Richard I., Dahlberg, Steve, Nathwani, Bharat N., Banks, Peter M., Miller, Thomas P., Grogan, Thomas M.

“…The objectives of this study were (1) to determine the clinical presentation and natural history associated with two newly recognized pathologic entities…”
Get full text

Prognostic significance of the Ki-67 : associated proliferative antigen in aggressive non-Hodgkin's lymphomas : a prospective Southwest oncology group trial by MILLER, T. P, GROGAN, T. M, SCHNITZER, B, TUBBS, R. R, GAYNOR, E. R, FISHER, R. I, DAHLBERG, S, SPIER, C. M, BRAZIEL, R. M, BANKS, P. M, FOUCAR, K, KJELDSBERG, C. R, LEVY, N, NATHWANI, B. N

“…The growth fraction of tumors from patients with non-Hodgkin's lymphomas (NHL) has been shown to correlate with survival in retrospective studies. The growth…”
Get full text

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy by Dana, B W, Dahlberg, S, Nathwani, B N, Chase, E, Coltman, C, Miller, T P, Fisher, R I

“…We reviewed survival data of patients with low-grade lymphoma entered on Southwest Oncology Group (SWOG) lymphoma trials in 1972 to 1983 to determine the…”
Get more information

Neural Cell Adhesion Molecule-Positive Peripheral T-Cell Lymphoma: A Rare Variant With a Propensity for Unusual Sites of Involvement by Kern, W.F., Spier, C.M., Hanneman, E.H., Miller, T.P., Matzner, M., Grogan, T.M.

“…A distinct subset of patients with peripheral T-cell lymphoma (PTCL) is described which reacts with Leu-19 (CD56), an antibody that has been shown to identify…”
Get full text

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy by Dalton, W S, Grogan, T M, Meltzer, P S, Scheper, R J, Durie, B G, Taylor, C W, Miller, T P, Salmon, S E

“…The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs. Tumor…”
Get more information

Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial by Miller, TP, Grogan, TM, Dahlberg, S, Spier, CM, Braziel, RM, Banks, PM, Foucar, K, Kjeldsberg, CR, Levy, N, Nathwani, BN

“…The growth fraction of tumors from patients with non-Hodgkin's lymphomas (NHL) has been shown to correlate with survival in retrospective studies. The growth…”
Get full text

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil by Miller, T P, Grogan, T M, Dalton, W S, Spier, C M, Scheper, R J, Salmon, S E

“…P-glycoprotein is a transmembrane protein thought to function as an efflux pump to detoxify cells. It is associated with multidrug resistance in laboratory…”
Get more information

Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration by Pennock, G D, Dalton, W S, Roeske, W R, Appleton, C P, Mosley, K, Plezia, P, Miller, T P, Salmon, S E

“…Aside from its more conventional uses as a cardiovascular drug, the calcium channel blocker verapamil has recently been added to chemotherapeutic regimens to…”
Get more information

Independent Prognostic Significance of a Nuclear Proliferation Antigen in Diffuse Large Cell Lymphomas as Determined by the Monoclonal Antibody Ki-67 by Grogan, Thomas M., Lippman, Scott M., Spier, Catherine M., Slymen, Donald J., Rybski, James A., Rangel, Catherine S., Richter, Lynne C., Miller, Thomas P.

“…To assess the prognostic significance of the growth fraction in diffuse large cell lymphoma (DLCL), we studied 105 DLCL patients with the monoclonal antibody…”
Get full text

Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease : a Southwest oncology group randomized study by FABIAN, C. J, MANSFIELD, C. M, DAHLBERG, S, JONES, S. E, MILLER, T. P, VAN SLYCK, E, GROZEA, P. N, MORRISON, F. S, COLTMAN, C. A, FISHER, R. I

“…To determine if low-dose involved field radiation after complete remission induction with chemotherapy is effective in preventing relapse and improving…”
Get full text

Follicular lymphomas: do histologic subtypes predict outcome? by Miller, T P, LeBlanc, M, Grogan, T M, Fisher, R I

“…There has been a long history of debate as to whether histologic subtypes of follicular lymphoma are associated with unique outcomes. The controversy has been…”
Get more information

Multidrug-Resistant Myeloma: Laboratory and Clinical Effects of Verapamil as a Chemosensitizer by Salmon, Sydney E., Dalton, William S., Grogan, Thomas M., Plezia, Patricia, Lehnert, Manfred, Roe, Denise J., Miller, Thomas P.

“…Verapamil was evaluated as a chemosensitizer for reversing multidrug resistance in multiple myeloma both in vitro and in clinical trials. Bone marrows from 59…”
Get full text

The diagnosis of potentially fatal asthma in hospitalized adults. Patient characteristics and increased severity of asthma by Miller, T P, Greenberger, P A, Patterson, R

“…We evaluated various patient characteristics in patients hospitalized for asthma during 1987 to 1990. Potentially fatal asthma was identified in 26 of 87 adult…”
Get more information

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience by Dixon, D O, Neilan, B, Jones, S E, Lipschitz, D A, Miller, T P, Grozea, P N, Wilson, H E

“…To study the influence of chronologic age on treatment outcome in patients with advanced, diffuse large-cell (histiocytic) lymphoma (DHL), we reviewed the…”
Get more information

Correlates of Memory Decline: A 4-Year Longitudinal Study of Older Adults With Memory Complaints by Taylor, Joy L, Miller, Terry P, Tinklenberg, Jared R

“…Change in memory performance and its correspondence to change in speed of performance and self-reported memory functioning were investigated longitudinally in…”
Get full text